Publications and presentations
October 24, 2026
ESMO Congress
A Phase 1/2 trial of zolucatetide (FOG-001), a first-in-class direct β-catenin:TCF inhibitor: updated safety and efficacy in patients with desmoid tumors
April 19, 2026
AACR Annual Meeting
Discovery of HeliconTM Peptides that Selectively Degrade the Agonist-Bound Androgen Receptor (ARON) in Prostate Cancer
March 5, 2026
InSiGHT Biennial Meeting
Zolucatetide (FOG‑001), a first‑in‑class direct β‑catenin:TCF inhibitor, exhibits activity in a familial adenomatous polyposis (FAP) patient with desmoid tumor (DT) and in a preclinical FAP model
November 21, 2025
SNO Annual Meeting
A Phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor – Safety and preliminary antitumor activity in patients with adamantinomatous craniopharyngioma
November 13, 2025
CTOS Annual Meeting
A Phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF inhibitor – Safety and preliminary antitumor activity in patients with desmoid tumors
October 25, 2025
PCF Scientific Retreat